On 24 July 2014, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product ibrutinib (Imbruvica) 140 mg hard capsule intended for the treatment of relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL).
Ibrutinib was designated as an orphan medicinal product on 26 April 2012 for treatment of MCL and on 12 March 2013 for treatment of CLL. Read more here.
No comments:
Post a Comment